Geron Corp (NASDAQ: GERN) is a commercial-stage biopharmaceutical company that develops and sells a telomerase inhibitor therapy for blood cancers. Revenue comes from product sales of RYTELO (imetelstat), which received FDA approval on June 6, 2024, for adult patients with lower-risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to, lost response to, or are ineligible for erythropoiesis-stimulating agents. Product revenue, net, grew from $76.5M in FY2024 to $183.6M in FY2025, representing 99.9% of total FY2025 revenues of $183.9M. A small royalty stream contributed $258K in FY2025. The company reported a net loss of $83.5M in FY2025, with selling, general and administrative expenses of $159.3M and research and development expenses of $71.4M. Geron is commercializing RYTELO in the U.S. and planning commercialization in the EU, with the addressable market limited to lower-risk MDS patients meeting the approved indication criteria.

Revenue model

Transactional product revenue from sales of RYTELO to patients with lower-risk MDS in the U.S., plus a small royalty stream. Product revenue, net was $183.6M in FY2025 versus $76.5M in FY2024. Royalties were $258K in FY2025.

Products and services

RYTELO (imetelstat), an FDA-approved telomerase inhibitor for lower-risk MDS with transfusion-dependent anemia. Approved June 6, 2024. EU commercialization planned as of the 10-K filed 2026-03-02.

Customers and end markets

Adult patients with lower-risk MDS requiring four or more red blood cell units over eight weeks who have not responded to or are ineligible for erythropoiesis-stimulating agents. End market is hematology/oncology in the U.S., with EU expansion planned.

Value-chain role

Commercial-stage drug developer and seller. Relies on third-party manufacturers, suppliers, and service providers for production. Carries debt under the Pharmakon Loan Agreement and a Royalty Pharma Agreement as of FY2025.

Geographic exposure

Primarily U.S. commercial operations as of FY2025. EU commercialization planned but not yet generating revenue as of the 10-K filed 2026-03-02.

Source: SEC 10-K, filed 2026-03-02

Industry: Pharmaceutical Preparations Peers: CareDx Inc Cogent Biosciences Inc Design Therapeutics Inc Editas Medicine Inc Erasca Inc Rocket Pharmaceuticals Inc Keros Therapeutics Inc Kura Oncology Inc POINT Biopharma Global Inc.